CIP
BMRN icon

Capital Insight Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Insight Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,834
Closed -$200K – 163
2025
Q1 		$200K Buy
+2,834
New +$191K 0.04% 157
2024
Q3 		– Sell
-2,450
Closed -$202K – 159
2024
Q2 		$202K Buy
2,450
+60
+3% +$5K 0.04% 156
2024
Q1 		$209K Buy
+2,390
New +$214K 0.04% 160

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Insight Partners's BMRN Position: Q2 2025 in Review

Capital Insight Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 2,834 shares — an estimated $200K sold.

Capital Insight Partners first reported a position in BMRN in Q1 2024 and held it in 3 quarters. The position peaked at $209K in Q1 2024. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Capital Insight Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capital Insight Partners sold 2,834 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $200K.
  • Capital Insight Partners first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Capital Insight Partners's BioMarin Pharmaceuticals position peaked at $209K in Q1 2024.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Capital Insight Partners's 13F filing for Q2 2025, filed 17 Jul 2025.